Under construction – not a live service
Sign in
Taking people in ChinaPhase 2

Tests PF-07328948 pill in adults with heart failure

Tests a new study pill against a placebo in adults with heart failure.

Plain-language title generated from the registry record
Registry title: A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

Key facts

Where
Beijing, Changchun, Changsha, Guangzhou, Haikou, Hengyang, Jinan, Lanzhou, Shanghai, Shijiazhuang, Tianjin, and Xi'an, ChinaSee the 13 sites
Phase
Phase 2

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 79 years old?

Source: NCT06991257, who can take part

Where in China

  • Peking University First HospitalBeijing, ChinaTaking people
  • China-Japan Union HospitalChangchun, ChinaTaking people
  • The Second Xiangya Hospital of Central South UniversityChangsha, ChinaTaking people
  • Guangdong Provincial People's HospitalGuangzhou, ChinaTaking people
  • Hainan General HospitalHaikou, ChinaTaking people
  • The First Affiliated Hospital of University of South ChinaHengyang, ChinaTaking people
  • Jinan Central HospitalJinan, ChinaTaking people
  • Lanzhou University Second HospitalLanzhou, ChinaTaking people
  • Shanghai Tongji HospitalShanghai, ChinaTaking people
  • Zhongshan Hospital,Fudan UniversityShanghai, ChinaTaking people
  • The First Hospital of Hebei Medical UniversityShijiazhuang, ChinaTaking people
  • Tianjin People's HospitalTianjin, ChinaTaking people
  • Shaanxi provincial people's hospitalXi'an, ChinaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Pfizer
Trial code
NCT06991257EU 2024-518438-94-00
Record updated
23 October 2026
Original description
The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).Read full original descriptionShow less

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN ORAL BRANCHED-CHAIN KETOACID DEHYDROGENASE KINASE INHIBITOR, PF-07328948, IN ADULTS WITH HEART FAILURE (BRANCH-HF)

The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).

Inclusion: aged 18 years to < 80 years; clinically confirmed to have a diagnosis of heart failure for at least 3 months; New York Heart Association Class II-IV symptoms; left ventricular ejection fraction greater than 40%; Kansas City Cardiomyopathy Questionnaire-23 Total Symptom Score < 85; Six-minute walking distance greater than 75 meters.

Exclusion: Major surgery scheduled for the duration of the study, affecting walking ability in the opinion of the study doctor; Prior intolerance/known hypersensitivity to an SGLT2 inhibitor or contraindication to an SGLT2 inhibitor; Type 1 diabetes mellitus, liver cirrhosis or any condition that can possibly affect how the medicine is absorbed into the body; History of heart transplantation, or currently listed for a heart transplant, or current planned use of IV vasodilators and/ or inotropes.

This study is seeking participants who are:.

ClinicalTrials.gov NCT06991257 · EU CTIS 2024-518438-94-00